Savara Inc.

Savara announces EAP for molgramostim for aPAP patients in select geographies where it's not commercially available, pending local regulatory compliance. The program is reviewed and allowed by the FDA, accepting requests from eligible patients in North America and Europe, with plans to expand through 2026.

Savara Inc. appoints Braden Parker as Chief Commercial Officer to oversee global strategy for molgramostim in aPAP, with a potential BLA submission to the FDA in H1 2025.

Molgramostim showed significant improvement in disease severity score (DSS), DLCO% responder analysis, SGRQ Total Score, and GGO score compared to placebo at Weeks 24 and 48 in aPAP patients, according to IMPALA-2 trial data presented at ERS 2024.